PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function.

Macrophages are central in orchestrating the clearance of apoptotic cells and cellular debris during inflammation, with the mechanism(s) regulating this process remaining of interest. Herein, we found that the n-3 docosapentaenoic acid-derived protectin (PDn-3 DPA) biosynthetic pathway regulated the differentiation of human monocytes, altering macrophage phenotype, efferocytosis, and bacterial phagocytosis. Using lipid mediator profiling, human primary cells and recombinant enzymes we found that human 15-lipoxygenases initiate the PDn-3 DPA pathway catalyzing the formation of an allylic epoxide. The complete stereochemistry of this epoxide was determined using stereocontrolled total organic synthesis as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid (16S,17S-ePDn-3 DPA). This intermediate was enzymatically converted by epoxide hydrolases to PD1n-3 DPA and PD2n-3 DPA, with epoxide hydrolase 2 converting 16S,17S-ePDn-3 DPA to PD2n-3 DPA in human monocytes. Taken together these results establish the PDn-3 DPA biosynthetic pathway in human monocytes and macrophages and its role in regulating macrophage resolution responses.

Introduction

Macrophages are central in orchestrating host responses to tissue injury and infections (Fredman et al., 2014, Gordon and Mantovani, 2011, Pierdomenico et al., 2015). The biological actions of these cells are associated with their phenotype, where classically activated macrophages are central in the initiation and propagation of the inflammatory response, whereas alternatively activated macrophages orchestrate tissue repair and regeneration (Dalli and Serhan, 2016, Gordon and Mantovani, 2011, Morris et al., 2010). Investigations into the cellular mechanisms underlying these distinct biological functions demonstrate that each macrophage subtype produces a characteristic repertoire of bioactive molecules, including cytokines and lipid mediators (LMs) (Dalli and Serhan, 2016, Gordon and Mantovani, 2011). In this context, recent studies demonstrate that, while classically activated macrophages and alternatively activated macrophages produce both inflammation initiating eicosanoids and pro-resolving mediators, their LM phenotypes differ. Indeed, classically activated macrophages produce higher amounts of pro-inflammatory eicosanoids, whereas alternatively activated macrophages produce higher levels of the recently identified specialized pro-resolving mediators (SPMs) (Dalli and Serhan, 2012). Tissue macrophages arise during either embryonic development or are differentiated in situ from monocyte precursors (Kopf et al., 2015). Mechanisms that dictate monocyte differentiation to different macrophage phenotypes are of relevance in determining whether inflammation is perpetuated or resolves, thus permitting regain of function.

SPMs are produced via the stereoselective conversion of essential fatty acids. The first SPMs identified were the lipoxins (LX) that are produced from arachidonic acid and carry potent leukocyte directed actions (Serhan et al., 1984). The D-series resolvins (RvD) produced from docosahexaenoic acid (DHA) and the E-series resolvins (RvE) produced from eicosapentaenoic acid also display leukocyte-directed actions (Chiang and Serhan, 2017). In addition, RvEs regulate platelet response (Dona et al., 2008) and neutrophil apoptosis (El Kebir et al., 2012), while the RvDs regulate vascular smooth muscle cell migration, a key process in the development of intimal hyperplasia (Mottola et al., 2017). Recently, we found that n-3 docosapentaenoic acid (DPA) is also a substrate for conversion to a new series of pro-resolving mediators, which include the n-3 DPA-derived protectins (PDn-3 DPA) (Dalli et al., 2013a). These mediators were initially identified in self-limited inflammatory exudates, with their production coinciding with monocyte/macrophage trafficking to the site. Human primary macrophages also produce these mediators. Of note, PD1n-3 DPA and PD2n-3 DPA carry potent leukocyte directed actions, reducing neutrophil recruitment as well as the production of inflammatory cytokines, including monocyte chemoattractant protein-1, during sterile inflammation (Dalli et al., 2013a). These actions were also found with human primary cells, where PDn-3 DPA reduce human neutrophil-endothelial cell interactions, neutrophil chemotaxis, and increased macrophage phagocytosis. The complete stereochemistry of the first member of this family of mediators, PD1n-3 DPA, was recently established as 10R,17S-dihydroxydocosa-7Z,11E,13E,15Z,19Z-pentaenoic acid (Aursnes et al., 2014). In humans, PD1n-3 DPA is upregulated in colon samples from IBD patients and displays potent tissue protective actions in mice during experimental colitis, reducing leukocyte-mediated tissue damage (Gobbetti et al., 2017).

The PDn-3 DPA biosynthetic pathway in human monocytes and macrophages is proposed to be initiated by 15-lipoxygenases (LOX), which convert n-3 DPA to an intermediate epoxide that in turn is enzymatically hydrolyzed to PD1n-3 DPA (Aursnes et al., 2014) and PD2n-3 DPA (16,17R-dihydroxy-7Z,10,13,14,19Z-docosapentaenoic acid) (Dalli et al., 2013a). Given the potent biological actions of PDn-3 DPA, and the central role of the proposed epoxide intermediate in the formation of these pro-resolving mediators, it was deemed important to (1) obtain evidence for its formation and role in the PDn-3 DPA biosynthesis, (2) establish the identity of enzyme(s) involved in the formation of this epoxide in human monocytes/macrophages, and (3) establish the biological actions of the PDn-3 DPA pathway in monocyte differentiation and macrophage responses. Using acid alcohol trapping, recombinant enzymes and human primary cells we found that both ALOX15 and ALOX15B catalyze the formation of 16,17S-ePDn-3 DPA. Using total organic synthesis we obtained stereochemically pure material, that, when incubated with primary human macrophages, was converted to both PD1n-3 DPA and PD2n-3 DPA. Furthermore, we found that the PDn-3 DPA pathway was important in regulating macrophage phenotype and function.

Results

Inhibition of 15-Lipoxygenase Activity in Human Monocytes Reduced Macrophage PDn-3 DPA Metabolome and Altered Macrophage Function

To obtain evidence for the role of the PDn-3 DPA biosynthetic pathway in regulating human macrophage function during monocyte differentiation, we incubated monocytes with an ALOX15 inhibitor and assessed the production of components within the PDn-3 DPA pathway. In human primary cells, using liquid chromatography-tandem mass spectrometry (LC/MS-MS), we identified 17-HDPA, PD1n-3 DPA, and PD2 n-3 DPA. In these incubations we also identified 10R/S,17S-diHDPA and 16R/S,17S-diHDPA, which correspond to the non-enzymatic products of the proposed epoxide intermediate in the PDn-3 DPA pathway (Figure 1A). Of note, incubation of monocytes with an inhibitor of ALOX15 led to a significant reduction in all the components of the PDn-3 DPA biosynthetic pathway, including the bioactive mediators PD1n-3 DPA and PD2n-3 DPA (Figure 1A; Table S1). The role of 15-lipoxygenases in PDn-3 DPA biosynthesis was further corroborated using cells from mice deficient in the murine homolog of this enzyme (ALOX15−/−), which demonstrated a significant reduction in all the components within the PDn-3 DPA pathway (Figure S1; Table S2).

Figure 1

Inhibiting 15-Lipoxygenase Activity Reduces PDn-3 DPA Production Dysregulating Macrophage Phenotype and Function

(A) Human monocytes were incubated with M-CSF (20 ng/mL) and either a ALOX15 inhibitor or vehicle (37°C, 5% CO2). On day 7 incubations were quenched, lipid mediators were extracted, identified, and quantified using lipid mediator profiling (see the STAR Methods for details). Results are mean ± SEM. n = 6 donors. *p < 0.05.

(B) Human monocytes were isolated and incubated with GM-CSF (20 ng/mL), IFN-γ (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells, and the expression of ALOX15 and ALOX15B was evaluated during the differentiation time course using flow cytometry. Results are mean ± SEM n = 4–6 donors per interval.

(C and D) Human monocytes were incubated with vehicle or ALOX15 inhibitor and then with M-CSF (20 ng/mL) for 7 days, and (C) expression of lineage markers was determined using fluorescently labeled antibodies and flow cytometry on day 7, and interrogated using OPLS-DA. n = 6 donors. (D) Phagocytosis of fluorescently labeled apoptotic cells investigated. Results for are mean ± SEM. n = 6 donors. *p < 0.05.

(E) Peritoneal macrophages were harvested from wild-type (WT) and ALOX15−/− mice, and the expression of lineage markers on CD64+ cells was determined using flow cytometry. Results were interrogated using OPLS-DA and are representative of n = 7 mice.

(F) Fluorescently labeled apoptotic cells were administered to WT and ALOX15−/− mice via intraperitoneal injection. After 1 hr peritoneal cells were harvested, and phagocytosis of apoptotic cells by CD64+ cells was evaluated using flow cytometry. Results are mean ± SEM. n = 7 mice per group. *p < 0.05.

Related to Figures S1 and S2 and Tables S1–S3.

Human leukocytes express two ALOX15 subtypes, therefore we sought to determine the temporal regulation of these enzymes in circulating monocytes and during monocyte-macrophage differentiation. Flow cytometric analysis demonstrated that human circulating monocytes express both ALOX15 and ALOX15B. The expression of both enzyme isoforms was upregulated during monocyte-to-macrophage differentiation. Of note, ALOX15 expression was higher in M2 differentiated cells, whereas the expression of ALOX15B was higher in M1 cells (Figure 1B). We next investigated the contribution of each of these two enzymes to PDn-3 DPA biosynthesis in human monocytes. Here we found that transfection of human monocytes with short hairpin RNA (shRNA) to ALOX15 reduced enzyme expression by ∼50% (p < 0.05; n = 5 donors), and the concentrations of several components of the PDn-3 DPA biosynthetic pathway, including PD1n-3 DPA and PD2n-3 DPA. Transfection of monocytes with shRNA to ALOX15B significantly reduced both enzyme expression (∼50%; p < 0.05; n = 5 donors) and PDn-3 DPA concentrations, albeit to a lesser extent than observed with shRNA to ALOX15 (Figure S2).

Given that PD1n-3 DPA and PD2n-3 DPA carry potent biological actions, we next questioned whether inhibition of this pathway during monocyte-to-macrophage differentiation influenced macrophage phenotype and function. We therefore assessed the expression of phagocytic receptors and adhesion molecules, which are linked with macrophage phenotype. Incubation of cells with ALOX15 inhibitor during monocyte differentiation led to the downregulation of several lineage markers, including CD206, CD163, and CD64, and a shift in macrophage phenotype (Figure 1C). This downregulation in phagocytic receptors was of functional consequence since inhibition of the PDn-3 DPA biosynthetic pathway also significantly downregulated the ability of human macrophages to uptake apoptotic cells (Figure 1D), a key pro-resolving action (Chiang and Serhan, 2017, Dalli and Serhan, 2016). This alteration in macrophage phenotype and function was also observed in tissue-resident macrophages from ALOX15-deficient animals. In these mice the expression of lineage markers on splenic macrophages, small peritoneal macrophages, and large peritoneal macrophages was altered with a downregulation in the expression of several markers including transforming growth factor β and T-cell immunoglubulin and mucin domain containing protein (TIM)-4 (Figure 1E). This was associated with a decreased ability of peritoneal macrophages to uptake apoptotic cells in vivo (Figure 1F; Table S3).

Having established a role of the PDn-3 DPA metabolome in regulating human macrophage function we next sought to obtain further evidence for the PDn-3 DPA biosynthetic pathway. Given the central role that the proposed 16,17S-ePDn-3 DPA plays in the biosynthesis of PDn-3 DPA, we sought to gain evidence for the formation of the proposed epoxide in human monocytes. For this purpose we assessed the formation of the epoxide using acid alcohol trapping, given that allylic epoxides are known to be unstable in aqueous solutions (Radmark et al., 1980). Using LC/MS-MS we identified four peaks, the first two gave a retention time (TR) and MS-MS fragmentation spectra corresponding with 10-methoxy,17S-hydroxy-docosapentaenoic acid (Figure 2A), whereas, the TR and MS-MS spectra for peaks III and IV corresponded to 16-methoxy,17S-hydroxy-docosapentaenoic acid (Figure 2A).

Figure 2

Human ALOX15 and Monocytes Produces a Novel 16,17S-ePDn-3 DPA

(A–C) Human monocytes (1 × 108 cells/mL; PBS; 37°C) (A), hr-ALOX15 (0.2 μM, 37°C [pH 8]) (B), and hr-ALOX15B (0.2 μM, 37°C [pH 8]) (C) were incubated with n-3 DPA (10 μM). After 3 min, incubations were quenched using acidified methanol, products extracted and identified using lipid mediator profiling. Left panels: MRM chromatogram for ion pairs m/z 375 > 277. Middle and right panels: MS-MS spectra employed in the identification of (middle panel) 10-methoxy,17S-hydroxy-7Z,11E,13E,15E,19Z-docosapentaenoic acid, (right panel) 16-methoxy,17S-hydroxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid in monocyte incubations. Results are representative of n = 4 donors and three independent experiments. Related to Figures S3 and S4.

Having obtained evidence for the formation of an epoxide intermediate by human monocytes we sought to determine whether ALOX15 enzymes were responsible for the formation of this intermediate. For this purpose we incubated human recombinant (hr) ALOX15 and hr-ALOX15B with n-3 DPA and assessed the acid alcohol trapping products using LC/MS-MS. This also gave four peaks that displayed essentially identical TR and MS-MS fragmentation spectra to the products obtained with primary human macrophages (Figures 2B and 2C). Thus, these results establish the role of human ALOX15 enzymes in the formation of 16,17S-ePDn-3 DPA.

Establishing the Complete Stereochemistry of 16S,17S-ePDn-3 DPA

Having obtained evidence for the formation of 16,17S-ePDn-3 DPA by human monocytes and the role of ALOX15 enzymes in its production, we next sought evidence for its role in the biosynthesis of PD1n-3 DPA and PD2n-3 DPA. For this purpose we obtained stereochemically pure material using total organic synthesis. The methyl ester of 16S,17S-ePDn-3 DPA was constructed via two key precursors (Figure 3A). These precursors were obtained using the following stereoselective reactions: a Katsuki-Sharpless epoxidation protocol (Kumar and Meshram, 2013) and one Z- and two E-selective Wittig reactions (Maryanoff and Reitz, 1989). The detailed description of the synthetic route is reported in Primdahl et al. (2017). The chemical purity and stereochemical integrity was validated using LC/MS-MS and nuclear magnetic resonance (NMR). The unambiguous assignment of the geometrical configurations of the olefins constituting the E,E,Z-triene moiety was performed using a 1H-1H COSY-45 NMR experiment (Figures 3B and S3). The following chemical shifts and coupling constants (J values) were recorded for the epoxy methyl ester of 16S,17S-ePDn-3 DPA: H12: 6.54 ppm, J = 14.7, 11.4 Hz; H14: 6.39 ppm, J = 15.3, 10.8 Hz; H13: 6.11 ppm, J = 14.8, 10.9 Hz; H11: 6.04 ppm, J = 11.2 Hz; H10 and H15: 5.48–5.32 ppm. Notably, H11 has a 3J-coupling constant to H10 with a value of 11.2 Hz, which is consistent with the assigned Z-rather than an E-configured C10-C11 double bond. The UV chromophore of this compound was also consistent with that of an allylic epoxide conjugated to a triene double-bond system, giving a λmaxMeOH of 280 nm with shoulders at 271 and 298 nm. These results confirm the stereochemistry of the synthetic epoxide as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid methyl ester.

Figure 3

Total Organic Synthesis of 16,17S-ePDn-3 DPA

(A) Outline of the synthetic strategy and key precursors employed in the preparation of 16S,17S-ePDn-3 DPA.

(B) Z and E stereochemical assignment for C=C using two-dimensional NMR spectroscopy. Contours denote positive and negative contours.

Related to Figures S3.

We next assessed whether the physical properties of the synthetic material obtained after lenient hydrolysis of the epoxy methyl ester matched those of the biological material. Incubation of the synthetic material in acid alcohol gave four distinct peaks with products displaying essentially identical TR and MS-MS fragmentation spectra as those obtained with hr-ALOX15 enzymes and human monocytes (Figures 2 and S4).

We next investigated whether the synthetic material was substrate for conversion to PD1n-3 DPA and PD2n-3 DPA. To this end, human macrophages were incubated with 16S,17S-ePDn-3 DPA and products were assessed using LC/MS-MS. In multiple reaction monitoring (MRM) we obtained two peaks. The first peak eluted with a TR of 13.8 min and gave characteristic fragments in the MS-MS that are consistent with PD1n-3 DPA. These fragments included the following diagnostic ions: m/z 361, m/z 183, and m/z 155 (Figures 4A and 4B). The second peak eluted with a TR of 15.2 min and gave ions in the MS-MS that were characteristic of PD2n-3 DPA including: m/z 361, m/z 263, and m/z 233 (Figures 4A and 4C). Of note, incubation of 16S,17S-ePDn-3 DPA in PBS only or with cells that had been previously kept at 100°C did not yield notable levels of these mediators (Figure 4D), indicating that the conversion of the epoxide to PD1n-3 DPA and PD2n-3 DPA was reliant on enzyme-mediated catalysis. In addition, these results establish the stereochemistry of the allylic epoxide intermediate as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid.

Figure 4

16S,17S-ePDn-3 DPA Is Precursor to PD1n-3 DPA and PD2n-3 DPA

16S,17S-ePDn-3 DPA (10 nM) was incubated with human macrophages (MΦ; 4 × 107 cells/mL) or inactivated human macrophages (i.e., 4 × 107 cells/mL previously been kept at 100°C for 1h). E. coli (2.5 × 108 colony-forming units [CFU]/mL) were added, cells incubated for 15 min, at 37°C, and incubations were quenched using ice-cold methanol. Products were then extracted and profiled using lipid mediator profiling. Vehicle denotes solution containing 0.1% EtOH in PBS.

(A) MRM chromatogram for PD1n-3 DPA (m/z 361 > 183) and PD2n-3 DPA (m/z 361 > 233).

(B and C) MS-MS spectra employed for identification of (B) PD1n-3 DPA (C) PD2n-3 DPA.

(D) PD1n-3 DPA and PD2n-3 DPA concentrations. Results are representative of n = 4 donors from two independent experiments. Results are means ± SEM. **p < 0.001, ***p < 0.0001 versus vehicle incubations. $p < 0.05 versus MΦ + E. coli incubations.

Epoxide Hydrolases Convert 16S,17S-ePDn-3 DPA to PD1n-3 DPA and PD2n-3 DPA

Having established a role for enzymes in catalyzing the conversion of 16S,17S-ePDn-3 DPA to PD1n-3 DPA and PD2n-3 DPA we next sought to establish the identity of these enzymes. Given the role that epoxide hydrolases play in converting allylic epoxides to bioactive mediators we assessed whether this class of enzymes was also involved in catalyzing the conversion of 16S,17S-ePDn-3 DPA in human monocytes. Incubation of human macrophages with the epoxide hydrolase inhibitor AUDA led to a reduction in the concentrations of both PD1n-3 DPA and PD2n-3 DPA (Figure 5A).

Figure 5

Epoxide Hydrolases Convert 16S,17S-ePDn-3 DPA to PD1n-3 DPA and PD2n-3 DPA

(A) Human monocytes (1 × 108 cells/mL) were incubated with vehicle (PBS + 0.1% DMSO) or AUDA (25 μM) for 20 min (at room temperature). Cells were then incubated with either vehicle (PBS + 0.1% EtOH) or 16S,17S-ePDn-3 DPA (10 nM). Incubations were quenched after 15 min and products profiled using LM profiling. Results are mean ± SEM. n = 4 donors and two independent experiments. **p < 0.01 versus vehicle; #p <0.05 versus monocyte incubations.

(B) 16S,17S-ePDn-3 DPA (10 nM) was incubated with human recombinant LTA4H (0.2 μM; Tris buffer). Incubations were quenched using ice-cold methanol and products identified using lipid mediator profiling. Left panel: MRM chromatogram m/z 361 > 263 (arrow denotes expected retention time for PD1n-3 DPA); right panel: MS-MS spectrum employed in the identification of 10,17S-hydroxy-7Z,11E,13E,15E,19Z-docosapentanenoic acid. Results are representative of n = 4 independent experiments.

Leukotriene A4 hydrolase (LTA4H) catalyses the hydrolysis of the allylic epoxide in LTA4 at the least sterically hindered carbon of the carbocation intermediate (Radmark et al., 1980, Rudberg et al., 2002) and is also expressed by human macrophages (Qiu et al., 2006). Therefore we questioned whether this enzyme was also responsible for catalyzing the conversion of 16S,17S-ePDn-3 DPA to PD1n-3 DPA. LC/MS-MS analysis of products obtained when LTA4H was incubated with 16S,17S-ePDn-3 DPA gave four peaks that were identified as the non-enzymatic hydrolysis products of 16S,17S-epoxy-PDn-3 DPA. The TR and MS-MS spectra of peaks I and II corresponded to 10R/S,17S-dihydroxy-7Z,11E,13E,15E,19Z-docosapentaenoic acid, whereas peaks III and IV were identified as 16R/S,17S-dihydroxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid (Figure 5B). For comparison LM profiling of the products obtained when LTA4H was incubated with LTA4 gave a major peak that eluted with a TR of 13.6 min, with the MS-MS spectrum corresponding to LTB4 (n = 4 incubations).

Another epoxide hydrolase expressed by human macrophages, which is also involved in the catalysis of allylic epoxides to bioactive mediators, is epoxide hydrolase 2 (EPHX2) (Deng et al., 2014). Thus, we next investigated whether this enzyme may play a role in the PDn-3 DPA biosynthetic pathway. Using flow cytometry we found that EPHX2 is expressed in monocytes and is upregulated during monocyte-to-macrophage differentiation (Figure 6A). Transfection of human monocytes with shRNA to EPHX2 led to a significant downregulation of PD2n-3 DPA and an increase in PD1n-3 DPA concentrations (Figure 6B). To further validate the role of EPHX2 in PD2n-3 DPA biosynthesis, we incubated hr-EPHX2 with 16S,17S-ePDn-3 DPA, which gave a peak with TR of 15.2 min and an MS-MS spectrum that corresponded to that of PD2n-3 DPA (Figure 6C). Of note, in these incubations we did not identify PD1n-3 DPA, suggesting that this enzyme selectively catalyzed the conversion of 16S,17S-ePDn-3 DPA to PD2n-3 DPA. Having found that hr-EPHX2 converted the epoxide to PD2n-3 DPA, we next co-incubated hr-ALOX15 with hr-EPHX2 to obtain further evidence for the PD2n-3 DPA biosynthetic pathway in human cells. LM profiling of these incubations gave a peak with TR and MS-MS spectrum corresponding to PD2n-3 DPA (Figure 6D). Of note, levels of this mediator in incubations with either hr-ALOX15 or EPHX2 were negligible. Similar findings were also made with incubations of hr-ALOX15B and EPHX2 (n = 3 distinct incubations). To further assess the role of EPHX2 in the biosynthesis of PD2n-3 DPA we incubated this enzyme with increasing concentrations of 16S,17S-ePDn-3 DPA and determined the reaction kinetics. Here we found that 16S,17S-ePDn-3 DPA was rapidly converted with a Vmax of 3,439 ± 1,539 mmol/min and a KM of 332 ± 188 μM (Figure 6E). Together these findings demonstrate that epoxide hydrolase enzymes are key in the conversion of 16S,17S-ePDn-3 DPA to PD1n-3 DPA and PD2n-3 DPA, and identify EPHX2 as the enzyme responsible for the conversion of 16S,17S-ePDn-3 DPA to PD2n-3 DPA.

Figure 6

EPHX2 Converts 16S,17S-ePDn-3 DPA to PD2n-3 DPA in Human Monocytes and Macrophages

(A) Human monocytes were isolated and differentiated using GM-CSF (20 ng/mL), IFN-γ (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells and the expression of EPHX2 during the differentiation time course was evaluated using flow cytometry. Results are mean ± SEM. n = 4–6 donors per interval.

(B) Human monocytes were transfected with shRNA to EPHX2 or CT shRNA (see the STAR Methods for details), cells were incubated for 10 hr at 37°C, then with E. coli for 45 min, and PDn-3 DPA concentrations evaluated using LM profiling. Results are mean ± SEM. n = 4 donors. *p < 0.05.

(C) 16S,17S-ePDn-3 DPA (10 nM) was incubated with hrEPHX2 (0.2 μM; Tris buffer). Incubations were quenched using ice-cold methanol and products identified using lipid mediator profiling. Left panel: MRM chromatogram m/z 361 > 233. Center panel: MS-MS spectrum employed in the identification of PD2n-3 DPA. Right panel: PD2n-3 DPA concentrations. Results are representative of n = 4 independent experiments. *p < 0.01 versus EPHX2 incubations.

(D) n-3 DPA (10 μM; Tris buffer) was incubated with hr-ALOX15 (0.2 μM), EPHX2 (0.2 μM), or a combination of the two enzymes. The incubations were quenched after 15 min and products extracted, identified, and quantified using lipid mediator profiling. Left panel: MRM chromatogram m/z 361 > 233; right panel: PD2n-3 DPA concentrations. Results are representative of n = 4 independent experiments. Results for right panels in (C) and (D) are means ± SEM. *p < 0.01 versus EPHX2 incubations; #p < 0.01 versus ALOX15 incubations.

(E) EPHX2 (0.2 μM, Tris buffer) was incubated with the indicated concentrations of 16S,17S-ePDn-3 DPA. Incubations were quenched and PD2n-3 DPA concentrations were determined using lipid mediator profiling. Results are mean ± SEM. n = 3 independent experiments.

PDn-3 DPA Regulate Human Macrophage Phenotype and Responses

Having found that inhibition of the PDn-3 DPA pathway alters macrophage phenotype we next sought to determine the role of select members of the PDn-3 DPA pathway during monocyte-to-macrophage differentiation. Co-incubation of human macrophages with an ALOX15 inhibitor and either 16S,17S-ePDn-3 DPA or PD1n-3 DPA upregulated the expression of several lineage markers, including CD163 and CD64, when compared with cells incubated with the inhibitor alone (Figure S5A). We next investigated whether the upregulation of these lineage markers was also associated with a restoration of the ability of human macrophages to clear apoptotic cells. Indeed, incubation of monocyte-dervied macrophages with 16S,17S-ePDn-3 DPA or PD1n-3 DPA rectified their ability to uptake apoptotic cells (Figures S5B and S5C). These restorative actions of PDn-3 DPA on macrophage function were also retained in vivo, where administration of PD1n-3 DPA rectified the expression of lineage markers on both splenic and peritoneal macrophages from ALOX15−/− mice (Figures 7A–7C; Table S3). Furthermore PD1n-3 DPA also upregulated the ability of peritoneal macrophages from ALOX15−/− mice to uptake apoptotic cells (Figure 7D) and bacteria (Figure 7E) in vivo. Together, these results demonstrate that the PDn-3 DPA pathway regulates key human macrophage functions in promoting the resolution of inflammation.

Figure 7

PD1n-3 DPA Rectifies Murine Resident Macrophage Phenotype and Function in ALOX15-Deficient Mice

(A–C) The expression of phenotypic markers was assessed in peritoneal and splenic macrophages from ALOX15−/− mice administered PD1n-3 DPA (10 ng/mouse for 7 days) or vehicle and WT mice using flow cytometry and macrophage phenotype interrogated using PLS-DA in (A) large peritoneal macrophages, (B) small peritoneal macrophages, and (C) splenic macrophages. Results are representative of n = 8 mice per group for (A and B) and n = 3–4 mice per group for (C).

(D and E) Mice were treated as in (A–C), and on day 7 administered fluorescently labeled (D) apoptotic cells (6 × 106 cells/mouse) or (E) E. coli (106 CFU/mouse) via an intraperitoneal injection. Peritoneal cells were collected after 1 hr and phagocytosis was assessed in (D) CD64+ large peritoneal macrophages (left panel) and small peritoneal macrophages (right panel), and (E) total CD64+ macrophage population. Results are mean ± SEM. n = 8 mice per group for (D) and n = 4 mice per group for (E). *p < 0.05.

(F) Structures are illustrated in most likely configurations based on biosynthetic evidence. The stereochemistries for PD1n-3 DPA and 16S,17S-PDn-3 DPA are established (Aursnes et al., 2015, Aursnes et al., 2014, Dalli et al., 2013a).

Related to Figures S5.

Discussion

Herein, we established the PDn-3 DPA biosynthetic pathway and the role of this pathway in regulating key macrophage responses during monocyte-to-macrophage differentiation. Results from the present experiments demonstrate that, in human and mouse monocytes and macrophages, 15-lipoxygenases are the initiating enzyme in the PDn-3 DPA pathway catalyzing the formation of 17S-HpDPA and 16S,17S-ePDn-3 DPA. The epoxide is then converted via enzymatic hydrolysis to PD1n-3 DPA and PD2n-3 DPA, whereby the conversion of 16S,17S-ePDn-3 DPA to PD2n-3 DPA is catalyzed by EPHX2. Inhibition of ALOX15 activity led to a significant alteration in the expression of lineage markers as well as the ability of macrophages to uptake apoptotic cells and bacteria, actions that were recovered by either 16S,17S-ePDn-3 DPA or PD1n-3 DPA.

During acute inflammation, monocytes are recruited to the site where under ideal conditions, they differentiate to macrophages with a tissue protective phenotype; a process that is central in the resolution of inflammation as well as tissue repair and regeneration (Bystrom et al., 2008, Dalli and Serhan, 2016). Chronic, unresolved inflammation is associated with dysregulated monocyte differentiation leading to macrophages displaying a pro-inflammatory phenotype (Dalli and Serhan, 2016, Newson et al., 2014, Sica et al., 2000). The mechanisms dictating whether monocytes differentiate into a tissue reparative or pro-inflammatory phenotype remain of interest. In the present study, we found that inhibiting ALOX15 expression and activity using both genetic and pharmacological approaches in mice and human primary cells dysregulated both macrophage phenotype and function (Figure 1). Incubation of monocytes throughout their differentiation into macrophages with either 16S,17S-ePDn-3 DPA or PD1n-3 DPA rescued the ability of macrophages to uptake apoptotic cells as well as upregulated the expression of lineage markers, including CD64 and CD163, which were decreased following ALOX15 inhibition. PD1n-3 DPA administration to ALOX15-deficient mice also rectified the expression of lineage markers on tissue-resident macrophages and the ability of peritoneal macrophages to uptake apoptotic cells and bacteria (Figure 7). Of note, ALOX15 is also the initiating enzyme in the RvD and LX biosynthetic pathway. Thus, while these results do not rule out the contribution of other ALOX15-derived pro-resolving mediators in the regulating monocyte-to-macrophage differentiation, they support a role for the PDn-3 DPA metabolome in regulating this process. The present findings also suggest that 16S,17S-ePDn-3 DPA is both a biosynthetic intermediate in the PDn-3 DPA pathway and exerts independent biological actions regulating cellular functions. These results are in line with findings made with other allylic epoxides including LTA4 (Ohishi et al., 1987) and 13S,14S-epoxy-maresin (Dalli et al., 2013c), which are also bioactive, regulating LM biosynthesis and cellular phenotype.

LMs are produced via the stereoselective conversion of essential fatty acids by their biosynthetic enzymes. Recent studies demonstrate that the differential regulation of the SPM biosynthetic enzymes may reflect disease status and contribute to the propagation of ongoing inflammation. In this context, for example, Fredman et al. (2014) found that phosphorylation of the ALOX5 changes the product profile of the enzyme, whereby phospho-ALOX5 translocates to the nuclear membrane where it couples with phospholipase A2 and LTA4H to produce the potent leukocyte chemoattractant LTB4. In the absence of this phosphorylation the enzyme is found in the cytosol, where it couples with ALOX15, producing the tissue-protective and pro-resolving mediators RvD1 and LXA4 (Fredman et al., 2014). These mechanisms are linked with disease onset/progression whereby, in atherosclerosis, recent studies identified an increased expression of phosphorylated ALOX5 and a decrease in the RvD1 to LTB4 ratio in aortic lesions (Fredman et al., 2016). These results may also shed light on the apparently discordant results obtained with omega-3 supplementation. This is because, if the expression and/or subcellular localization of SPM biosynthetic enzymes is dysregulated, the product profile will be altered and the expected beneficial actions via SPM production may be diminished. Thus, furthering our understanding on the biosynthetic pathways governing SPM biosynthesis is essential in order to gain better insights into disease etiopathology. The present studies focus on establishing the role of the PDn-3 DPA in cells of the monocytic lineage. These findings demonstrate that human ALOX15 and ALOX15B catalyze the first two steps in the PDn-3 DPA biosynthetic pathway yielding an allylic epoxide. Using total organic synthesis, we established the absolute stereochemistry of this epoxide as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid. Furthermore, using this synthetic material we found that 16S,17S-ePDn-3 DPA was converted to PD1n-3 DPA and PD2n-3 DPA by different epoxide hydrolase enzymes, where in human cells EPHX2 was found to catalyze the conversion of 16S,17S-ePDn-3 DPA to PD2n-3 DPA (Figure 7). Of note, we also found that LTA4H was not involved in the biosynthesis of PD1n-3 DPA.

In summation, the present findings establish the identity of enzymes involved in the PDn-3 DPA biosynthetic pathway, as well as the complete stereochemistry of the key intermediate in this pathway (Figure 7F). They also demonstrate that the PDn-3 DPA pathway plays a role in the differentiation of monocytes to macrophages, where inhibition of 15-lipoxygenase activity during monocyte-to-macrophage differentiation results in impaired monocyte-derived macrophage responses that are rescued by addition of PDn-3 DPA. Thus, these findings establish candidates in understanding the etiopathology of inflammatory diseases as well as targets for patient stratification and essential fatty acid supplementation.

Significance

Macrophages are central players in controlling the body’s response to both sterile injury and infections. During the course of inflammation monocytes are recruited to the site of injury and/or infections, where they differentiate to macrophages. The phenotype displayed by these macrophages dictates whether the cells promote the termination of inflammation or lead to chronicity, with the mechanisms that control the monocyte-to-macrophage differentiation process remaining of interest. In the present study, we found that inhibition of ALOX15 activity during monocyte-to-macrophage differentiation reduced PD production, altered human macrophage phenotype and their ability to clear dead cells, a key step in the termination of inflammation. Incubation of these cells with components of the PD biosynthetic pathway rectified these responses. We established the identity and complete stereochemistry of 16, a key intermediate in this pathway, and the role of human 15-lipoxygenases in producing this intermediate. We also provide evidence for a role of epoxide hydrolase enzymes in catalyzing the conversion of this intermediate to the pro-resolving mediators PD1 and PD2 in human monocytes. Here we found that EPHX2 selectively catalyzes the conversion of 16 to PD2. Together these results establish the PD pathway in human monocytes and the contribution of this pathway in monocyte-to-macrophage differentiation.

STAR★Methods

Key Resources Table

Contact for Reagent and Resource Sharing

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jesmond Dalli (j.dalli@qmul.ac.uk).

Experimental Model and Subject Details

Animal Studies

Healthy 6-11 week old male C57/Black6 wild type mice (Charles River) and ALOX15-/- (The Jackson Laboratory) mice were used in the reported studies. The experiments strictly adhered to UK Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986) and Laboratory Animal Science Association (LASA) Guidelines (Guiding Principles on Good Practice for Animal Welfare and Ethical Review Bodies, 3rd Edition, 2015). Animals were kept on a 12 h light dark cycle, with lights turned on at 7:00 h and lights turned off at 19:00h under specific pathogen free housing and had access to food and water ad libitum. Sample size was based on the statistical analysis of previous experiments and no mice were excluded. Animals were randomly assigned to control and experimental groups. The investigators were not blinded to group assignments.

Human Primary Cells

Healthy human peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte cones obtained from the NHS Blood and Transplant bank and experiments were conducted in accordance with a protocol approved by Queen Mary Research Ethics Committee (QMREC 2014:61) and in accordance with the Helsinki declaration. Informed consent was obtained from all volunteers. Given that cones were obtained from the NHS Blood and Transplant bank and volunteers were unidentified, no information was available on sex, age, their involvement in previous experiments or if they were drug or test naïve. Primary cells were incubated for at 37°C at 5 % CO2. The HL60 cell line was established in a female donor.

Method Details

Monocyte Incubations

Human PBMCs were isolated from healthy human volunteers purchased from the NHS Blood and Transplant bank and experiments conducted in Queen Mary Research Ethics Committee approval (QMREC 2014:61) and the Helsinki declaration. Here blood cones were used and PBMCs were isolated by density centrifugation where cells were layered on to Histopaque - 1077 (Sigma) and centrifuged for 30 minutes at 400 x g at room temperature (RT). Macrophages were prepared using published protocols (Dalli and Serhan, 2012) where PBMCs were plated into 10 cm tissue culture plates and incubated at 37°C for 30 min in PBS+/+. Non-adherent cells were then removed by adding PBS-/- and washed vigorously. Adherent cells (3 × 107 cells/incubation) were then incubated with vehicle (PBS+0.1% ethanol), 1 nM 16S,17S-ePDn-3 DPA or 1 nM PD1n-3 DPA in RPMI 1640 (Sigma) for 30 minutes at 37°C. These were then incubated with either vehicle or ALOX15 inhibitor (10 μM PD146176 (Sendobry et al., 1997); Cambridge Bioscience) in RPMI 1640 containing 10% human serum, 1% Penicillin-Streptomycin and 20 ng/mL M-CSF. The cells were incubated for 3 days at 37°C at 5% CO2 and the media together with mediators and inhibitors were added as above and the cells were incubated a further 4 days. For lipid mediator profiling of cell supernatant, RPMI 1640 Medium (no glutamine) with no phenol red was used. Cell supernatants were collected and placed in two volumes of methanol containing deuterium labelled internal standards (500 pg of d4-Prostaglandin (PG)E2, d5-LXA4, d4-RvD2, d4-Leukotriene (LT)B4 and d8-5S-Hydroxy-eicosatetraneoic acid; Cayman Chemicals). These were stored at -20°C until extraction (see below). In select experiments to obtain M1 macrophages adherent cells were cultured with GM-CSF (20ng/mL) for 6 days then with LPS (1ng/mL) and interferon-γ (20ng/mL) for 24h. To obtain M2 macrophages adherent cells where incubated with M-CSF (20ng/mL) for 7 days then with IL-4 (20ng/mL) for 48 h. In all cases the purity of the cell preparations ranged between 90-95%.

For human monocyte incubations we isolated monocytes from PBMCs using the EasySep™ Human Monocyte Isolation Kit, following manufacturer’s instruction where the purity of the resultant cell population was of ∼95%. Human monocytes (1 × 108 cells/mL) were incubated with n-3 DPA (10μM) and Escherichia coli (5 × 109 CFU/mL) in PBS at 37°C. Incubations were quenched using excess acidified methanol (apparent pH ∼3) containing deuterium labelled d4-LTB4 and products were extracted as detailed below.

In select experiments monocytes (1x108 cells/ml) were incubated with vehicle (PBS + 0.01% DMSO) or 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid (AUDA; 25μM) for 20 min at RT. Cells were then incubated with either vehicle (PBS + 0.1%EtOH) or 16S,17S-e-PDn-3 DPA (10nM) for 15 min. Incubations were then quenched and products identified and profiled using LM profiling as detailed below.

Monocytes (1.5x106 cells/ml) were suspended in phenol red free RPMI 1640 containing 10% human serum, 8μg/ml of polybrene and 50ng/ml of shRNA to ALOX15B or CT shRNA. The cell suspension was then centrifuged at 1000 x g for 90 min at 4°C. Cells were then plated and incubated for a further 12h at 37°C. Monocytes were then detached after 5 minutes incubation in 2mM EDTA in PBS-/-, and the expression of ALOX15B was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with E. coli (1:50 monocytes to bacteria) for 45 min at 37°C. Incubations were quenched using two volumes of ice-cold methanol and products profiled using lipid mediator profiling.

In separate experiments monocytes were plated in 6 well plates and incubated with phenol red free RPMI 1640 containing 10% human serum, 8μg/ml of polybrene and 2μg/ml of shRNA to ALOX15, EPHX2 or CT shRNA. The cell incubations were gently mixed for the first 5 hours, media was then removed and cells incubated with 15% DMSO in Hanks’ Buffered Saline Solution for 4 mins at 37°C. The solution was then removed, cells were rinsed with PBS and then incubated for a further 7h in phenol red free RPMI containing 10% human serum and 1% Penicillin-Streptomycin. Cells were then detached after 5 minutes incubation in 2mM EDTA in PBS-/-, and expression of ALOX15 and EPHX2 was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with E. coli as detailed above.

Mouse monocytes were isolated by adhesion of bone marrow cell suspension from WT and ALOX15-deficient mice to tissue culture dishes. After 45 min cell were detached and cell populations determined to be ∼80-90% monocytes. Monocytes (2 × 106 cells/mL) were incubated in phenol red free RPMI containing 0.1% FBS and E. coli (1 × 108 CFU/mL) at 37°C for 45 min. Incubations were quenched using 2 volumes of ice-cold methanol containing deuterium labelled internal standards and lipid mediators identified and quantified using lipid mediator profiling.

Enzyme Incubations

Human recombinant (hr)-ALOX15 (0.2μM; Novus Biologicals) or (hr)-ALOX15B (0.2μM; Cayman Chemicals) was incubated with n-3 DPA (10 μM) in Tris buffer (pH = 8.0) at RT for 2 min. Products were quenched using excess acidified methanol (apparent pH ∼3) containing deuterium labelled d4-LTB4 and extracted as detailed in the lipid mediator profiling section below. In select incubations hr-ALOX15 or hr-ALOX15B were incubated with EPHX2 (0.2μM; Cayman Chemicals) and n-3 DPA (10μM) in Tris buffer (pH = 8.0) at RT for 15 min. Incubations were quenched using ice-cold methanol and products extracted, identified and quantified as detailed below.

In select incubations EPHX2 (0.2μM) was incubated with 16S,17S-ePDn-3 DPA (10nM) in Tris buffer (pH = 8.0) at RT for 10 min; incubations were then quenched, and products identified and quantified as detailed below.

Flow Cytometry

Flow cytometry was used to determine the phenotypic lineage of the monocyte-derived macrophages using fluorescently conjugated antibodies. Cells were fixed in 1% paraformaldehyde (4% paraformaldehyde in PBS-/-) for 10 minutes at room temperature. Cells were incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4°C in staining solution (1:1 PBS with 0.02 % BSA and FC block): APC/Cy7 anti-human CD14 (clone 63D3, Biolegend), PE-Cyanine7 anti-human CD32 (clone 6C4, eBiosciences), Alexa Fluor (AF) 405 anti-ICAM-1 (clone 1A29, Novus), PE/Cy5 anti-CD64 (clone 10.1, Abcam), AF 488 anti-human CD68 (clone Y1/82A, Biolegend), Brilliant Violet (BV) 650 anti-human CD80 (clone 2D10, Biolegend), PerCP/Cy5.5 anti-human CD206 (clone 15-2, Biolegend) and PE-CF594 anti-human CD163 (clone GHI/61, BD Biosciences). LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter analysis, followed by analysis using FlowJo (Tree Star Inc., V10).

To determine the expression of PDn-3 DPA biosynthetic enzymes, monocytes and macrophages were incubated with M-CSF and IL-4 or GM-CSF, IFNγ and LPS for 7 days as detailed above. At the indicated intervals cells were collected, permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer’s instructions, non-specific binding was quenched using non-specific IgG (16mg/mL) and cells were then incubated with rabbit anti-human 15-LOX type 1, mouse anti-human 15-LOX type 2, and mouse anti-human EH2 for 30 min at 4°C. To determine the expression of 15-LOX type 2 and EH2, cells were then incubated with AF 488 goat anti-mouse IgG for 30 min at 4°C and staining evaluated using LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter data acquisition, followed by analysis using FlowJo (Tree Star Inc., V10).

In select experiments cells were collected from the peritoneum of WT and ALOX1- deficient mice by lavaging the peritoneum with PBS. Splenic cells were obtained following dissociation of spleens from WT and ALOX15-deficient mice using a 70 μM filter. The cells were counted and incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4°C in staining solution (1:1 PBS with 0.02 % BSA and TrueStain FC Blocking IgG): PE-Cy5 anti-mouse/human CD 11b (Clone M1/70, Biolegend), BV 650 rat anti-mouse I-A/I-E (MHC II) (Clone M5/114.15.2, Biolegend), APC-Cy7 rat anti-mouse F4/80 (Clone BM8, Biolegend), BV785 hamster anti-mouse CD 11c (Clone N418, Biolegend) and PerCP-eFluor710 rat anti-mouse TIM-4 (Clone 54 (RMT4-54), eBiosciences). For intracellular staining, cells were permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer’s instructions for 20 min at RT and then with fluorescently labelled antibodies in a 1:50 dilution for 30 minutes at 4°C in staining solution (1:10 Permeabilization buffer (10X) (eBiosciences) and PBS with 0.02 % BSA): AF 488 COX 2 (Clone (D5H5) XP ®, Cell Signaling Technologies), PE-Dazzle 594 rat anti-mouse IL-10 (Clone JES5-16E3, Biolegend), BV 421 mouse anti-mouse TGF-β1 (Clone TW7-16B4, Biolegend), PE sheep anti-mouse Arginase 1 (Cat # IC5868P, R&D) and AF 647 rabbit- anti-human iNOS (Clone 4E5, Novus). Non-specific binding was quenched using TruStain Fc-blocking IgG (anti-mouse CD16/32) and the staining was evaluated as above. For cells obtained from both in vivo efferocytosis and phagocytosis experiments non-sepcific binding was quenched as detailed above. Cells were then incubated in PBS-/- containing 0.02% BSA and either APC-Cy anti-mouse CD64 or PE anti-mouse CD64 (at 1:100 dilution) for 30 min at 4oC and staining evaluated.

Macrophage Incubations

In Vitro Efferocytosis

Macrophages, prepared as described above, were seeded into 96 well plates at 5 × 104 cells per well in RPMI 1640 medium with 10 % human serum at 37°C. Apoptotic cells were prepared by incubating the human promyelocytic leukemic cell line HL60 at 70°C for 2h yielding ∼60% Annexin V positive / propidium iodide negative cells and 35% Annexin V positive / propidium iodide positive cells using APC Annexin V Apoptotic Detection Kit with PI (Biolegend). These were then stained using PKH26 Red Fluorescent Cell Linker kit (Sigma) following manufacturer’s instructions and efferocytosis was assessed as in (Dalli and Serhan, 2012). In brief, fluorescently labelled apoptotic cells (1:3, macrophages to apoptotic cells) were added to the macrophages and incubated at 37°C for 45 minutes. Cells were washed with PBS and extracellular fluorescence was quenched using trypan blue (1:15 in PBS). Fluorescence was then measured using a FLUOstar Omega microplate reader (BMG Labtech). In select experiments apoptotic cells were labelled using PKH67 and incubated with macrophages as detailed above. Macrophage efferocytosis was then evaluated using an ImageStream X MK2 and analysis was performed using IDEAS® (Image Data Exploration and Analysis Software, Version 6.0).

In Vivo Efferocytosis

Mice were administered either vehicle or PD1n-3 DPA (10ng/mouse) via i.p. injection for 7 days. Apoptotic cells were prepared and labelled as detailed above using PKH67 dye. These (6x106 cells per mouse) were injected via intraperitoneal injection to WT and ALOX15-deficient mice. After 1h cells were collected by peritoneal lavages and incubated with an APC-Cy7 labelled anti-mouse CD64 antibody as detailed above and efferocytosis in CD64 positive macrophages was evaluated using Flow cytometry.

E. coli Incubations

Macrophages (2x106 cells) were incubated with E. coli (1x107 cells) for 30 minutes at 37°C. Incubations were quenched using two volumes of ice-cold methanol containing deuterium labelled internal standards (500 pg each of d4-PGE2, d5-LXA4, d4-RvD2, d4-LTB4 and d8-5S-HETE, Cayman Chemicals). Samples were then stored at -20°C prior to extraction and lipid mediator profiling.

In Vivo Phagocytosis

Mice were administered either vehicle or PD1n-3 DPA (10ng/mouse) via i.p. injection for 7 days. E. coli were labelled using LIVE/DEAD BacLight Bacterial Viability dye following manufacturer’s instructions. Fluorescently labelled bacteria were then injected via intraperitoneal injection to WT and ALOX15-deficient mice and peritoneal lavages were collected after 1h. Cells were stained using fluorescently labelled PE anti-mouse CD64 antibody and bacterial phagocytosis was evaluated using flow cytometry as detailed above.

Lipid Mediator Profiling

Proteins were allowed to precipitate by keeping samples at -20°C for 30 minutes. Deuterium-labelled standards, d4-PGE2, d5-LXA4, d4-RvD2, d4-LTB4 and d8-5S-HETE were used to aid in identification and quantification of lipid mediators (Dalli and Serhan, 2012). Following protein precipitation, samples were then extracted using an ExtraHera (Biotage) with ISOLUTE C18 columns (500 mg, 3 mL; Biotage). This involved the conditioning of the Solid-phase ISOLUTE C18 500 mg/3 mL columns with methanol for 60 seconds using 2.5 bar positive pressure. Samples, brought to 10 mL with pH 3.5 water, were loaded onto the columns for 90 seconds using 2.5 bar positive pressure. The acid in the C18 columns was neutralised by washing the columns with 2 mL pH 7 water for 45 seconds using 2.5 bar positive pressure, followed by the hexane wash to elute hydrophobic molecules. This was done four times with 3 mL hexane using 2.5 bar positive pressure for 60 seconds for each wash. Mediators were then eluted into collection tubes with the addition of 5 mL methyl formate at 1.5 bar positive pressure for 120 seconds. Products were brought to dryness using a gentle nitrogen stream and TurboVap LV (Biotage), these were then suspended in phase containing methanol and water, 1:1 (vol/vol).

An LC-MS-MS system, comprising of a Qtrap 5500 (AB Sciex) or Qtrap 6500 plus (AB Sciex), Shimadzu SIL-20AC autoinjector, LC-20AD binary pump (Shimadzu Corp.) and Agilent C18 Poroshell column (150 mm × 4.6 mm × 2.7 μm) was used to profile lipid mediators. The gradient was initiated at 20:80:0.01 (vol/vol/vol) methanol/water/acetic acid for 0.2 mins this was ramped to 50:50:0.01 (vol/vol/vol) over 12 seconds, maintained for 2 minutes, then ramped to 80:20:0.01 (vol/vol/vol) over 9 minutes, and maintained for 3.5 minutes. The ratio was then ramped to 98:2:0.01 (vol/vol/vol) for 5.5 minutes. The flow rate was kept at 0.5 mL/minute throughout.

Mediator concentrations were determined using multiple reaction monitoring (MRM) using signature parent ion (Q1) and characteristic daughter ion (Q3) pairs. A minimum of six diagnostic ions were used to confirm their identities, using published criteria (Dalli and Serhan, 2012). The peak area of the MRM transition and linear calibration curves with an r2 value of 0.98 to 0.99 were used to quantify each of the molecules. The detection limit was ∼0.1 pg.

Total Organic Synthesis of 16S,17S-ePDn-3 DPA

Unless stated otherwise, all commercially available reagents and solvents were used in the form they were supplied without any further purification. The stated yields are based on isolated material. All reactions were performed under an argon atmosphere using Schlenk techniques. Reaction flasks were covered with aluminium foil during reactions and storage to minimize exposure to sunlight. Thin layer chromatography was performed on silica gel 60 F254 aluminium-backed plates fabricated by Merck. Flash column chromatography was performed on silica gel 60 (40-63 μm) produced by Merck. NMR spectra were recorded on a Bruker AVI600, Bruker AVII400 or a Bruker DPX300 spectrometer at 600 MHz, 400 MHz or 300 MHz respectively for 1H NMR and at 150 MHz, 100 MHz or 75 MHz respectively for 13C NMR. Coupling constants (J) are reported in hertz and chemical shifts are reported in parts per million (δ) relative to the central residual protium solvent resonance in 1H NMR (CDCl3 = δ 7.26, DMSO-d = δ 2.50, benzene-d = δ 7.16 and MeOD-d = δ 3.31 ppm) and the central carbon solvent resonance in 13C NMR (CDCl3 = δ 77.00, DMSO-d = δ 39.43, benzene-d = δ 128.06 and MeOD-d = δ 49.00 ppm). Mass spectra were recorded at 70 eV on Micromass Prospec Q or Micromas QTOF 2W spectrometer using EI, ES or CI as the methods of ionization. High resolution mass spectra were recorded on Micromass Prospec Q or Micromas QTOF 2Wspectrometer using EI or ES as the methods of ionization. Optical rotations were measured using a 0.7 mL cell with a 1.0 dm path length on an Anton Paar MCP 100 polarimeter. HPLC analyses were performed on an Agilent Technologies 1200 Series instrument with diode array detector set at 254 nm and equipped with a C18 stationary phase (Eclipse XDB-C18 5 μm 4.6 × 150 mm), applying the conditions stated. GLC analyses were performed on an Agilent 7820A with a FID detector, HP-5 capillary column, with helium as the carrier gas and by applying the conditions stated.

Synthesis of methyl (7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoate (methyl ePD1n-3 DPA)

The epoxy aldehyde (2E,4E)-5-((2S,3S)-3-((Z)-pent-2 en-1-yl)oxiran-2-yl)penta-2,4-dienal was prepared from commercially available 2-(triphenyl-λ5-phosphanylidene)acetaldehyde and (2R,3S)-3-((Z)-pent-2-en-1-yl)oxirane-2-carbaldehyde as described (Aursnes et al., 2015). The Wittig-salt methyl (Z)-10-(iodotriphenyl-λ5-phosphanyl)dec-7-enoate was made according to literature protocols (Primdahl et al., 2017)

Z-Selective Wittig Reaction

This reaction was performed as earlier reported (Aursnes et al., 2014). In brief, 1.3 equiv. of the Wittig salt methyl (Z)-10-(iodotriphenyl-λ5-phosphanyl)dec-7-enoate was dissolved in THF and then HMPA was added. This solution was cooled to −78°C. Then NaHMDS (0.60 M in toluene, 1.3 equiv.) was added drop-wise. The reaction mixture was stirred for 30 min at this temperature. The epoxy aldehyde (2E,4E)-5-((2S,3S)-3-((Z)-pent-2 en-1-yl)oxiran-2-yl)penta-2,4-dienal (1.0 equiv.) was azeotroped twice with 2-methyltetrahydrofuran, then dissolved in THF, and cooled to −78°C. This solution was added dropwise to the reaction flask via cannula and the resulting reaction mixture was stirred for 1 h at −78°C. Then the temperature of the reaction mixture was quickly warmed to −20°C and kept at this temperature for a few minutes. The reaction mixture was then quenched by the addition of an equal amount of phosphate buffer (0.2 M, pH = 7) as the volume of the reaction mixture. The phases were separated, and the aqueous phase was extracted with Et2O. The combined organic layers were dried with Na2SO4, then filtrated, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography that had been deactivated by a solution containing Et3N (3%), Et2O (20%) in heptane. The product was eluted with Et2O (25%) in heptane to provide the titled epoxy methyl ester as a colorless oil. Physical and spectral data: [α]20D = −38 (c = 0.20, CHCl3); UV (hexane) λmax 270, 281, 292; 1H NMR (600 MHz, benzene-d) δ 6.54 (dd, J = 14.7, 11.4 Hz, 1H), 6.39 (dd, J = 15.3, 10.8 Hz, 1H), 6.11 (dd, J = 14.8, 10.9 Hz, 1H), 6.04 (t, J = 11.2 Hz, 1H), 5.51 – 5.31 (m, 6H), 3.36 (s, 3H), 3.06 (dd, J = 7.8, 1.8 Hz, 1H), 2.91 (t, J = 7.1 Hz, 2H), 2.71 (td, J = 5.2, 2.0 Hz, 1H), 2.24 (dq, J = 13.8, 6.4 Hz, 1H), 2.20 – 2.14 (m, 1H), 2.09 (t, J = 7.4 Hz, 2H), 1.94 (dq, J = 23.1, 8.4, 7.5 Hz, 4H), 1.53 (p, J = 7.4 Hz, 2H), 1.25 – 1.13 (m, 4H), 0.88 (t, J = 7.5 Hz, 3H). 13C NMR (151 MHz, C6D6) δ 173.3, 134.7, 134.1, 132.3, 131.4, 131.4, 130.8, 129.0, 128.9, 127.6, 123.2, 60.3, 57.7, 51.0, 34.1, 30.1, 29.6, 29.0, 27.4, 26.7, 25.2, 21.0, 14.4; HRMS (TOF ES+): Exact mass calculated for C23H34O3Na [M+Na]+: 381.2400, found 381.2400. TLC (heptane/Et2O, 74:26 CAM stain): R = 0.21.

(7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoic acid (ePDn-3 DPA). Methyl (7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoate (100 μg in hexane/Et2O) was dried under a gentle stream of nitrogen and then dissolved in 500 μL of THF. For additional details on the preparation of this compound, see (Primdahl et al., 2017). This THF solution was cooled to -78°C using a dry ice/isopropanol cooling bath. Then 100 μL of aqueous 1.0 M LiOH solution was slowly added via a Hamilton syringe at -78°C. Additional 100 μL of H2O was added and the vial was covered with aluminium foil and left stirring for 10 h. The solution above the precipitated lithium salt was gently removed by using a syringe. Next, the THF-solution was dried under a gentle stream of nitrogen before quantification using UV (hexane) λmax 271 (log ε 3.58), 280 (log ε 4.08), 298 (log ε 2.69) nm. After quantification and removal of hexane, the acid was suspended in 50 μL PBS+/+ pH = 7.45. The PBS solution was kept on solid dry ice in a closed container prior to use, and was used for incubation biological experiments. The structure of the chemical labile free acid was determined indirectly by using UV and LC/MS-MS experiments.

Quantification and Statistical Analysis

Results are represented as mean ± SEM. Differences between groups were assessed using one-sample t test (normalized data), Student’s t test (2 groups), 1-way ANOVA (multiple groups) followed by post hoc Dunnett’s test using GraphPad Prism 6 software. Investigators were not blinded to group allocation or outcome assessment. The criterion for statistical significance was P ≤ 0.05. Sample sizes for each experiment were determined on the variability observed in prior experiments (Dalli and Serhan, 2016) and preliminary experiments. Partial least squares-discrimination analysis (PLS-DA) and principal component analysis (PCA) (Janes and Yaffe, 2006) were performed using SIMCA 14.1 software (Umetrics, Umea, Sweden) following mean centering and unit variance scaling of LM levels. PLS-DA is based on a linear multivariate model that identifies variables that contribute to class separation of observations on the basis of their variables (LM levels). During classification, observations were projected onto their respective class model. The score plot illustrates the systematic clusters among the observations (closer plots presenting higher similarity in the data matrix). Loading plot interpretation identified the variables with the best discriminatory power (Variable Importance in Projection greater than 1) that were associated with the distinct intervals and contributed to the tight clusters observed in the Score plot.

Data and Software Availability

Data are available upon request to the Lead contact.

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies
APC/Cy7 anti-human CD 14	Biolegend	Clone 63D3;Cat # 367107
PE-Cy7 anti-human CD 32	eBiosciences	Clone 6C4;Cat # 25-0329-41
PE-Cy5 anti-CD 64	Abcam	Clone 10.1;Cat # ab192338
Alexa Fluor 405 anti-ICAM-1	Novus	Clone 1A29;Cat # NBP2-22541
Alexa Fluor anti-human 488 CD 68	Biolegend	Clone Y1/82A;Cat # 333811
Brilliant Violet anti-human 650 CD 80	Biolegend	Clone 2D10;Cat # 305227
PerCP-Cy5.5 anti-human CD 206	Biolegend	Clone 15-2;Cat # 321121
PE-CF 594 mouse anti-human CD 163	BD Biosciences	Clone GHI/61;Cat # 562670
Monoclonal anti-ALOX15B	Sigma	Clone 4A7Cat # SAB1402114-100UG
EPXH2 antibody [2F2]	Gene Tex	Cat # GTX84567
Alexa Fluor 488 Goat anti-mouse IgG (H + L)	Invitrogen	Cat # A11029
Alexa Fluor 647 15-Lipoxygenase 1 rabbit polyclonal	Bioss	Cat # bs-6505R-A647
APC-Cy7 anti-mouse CD 64	Biolegend	Clone X54-5/7.1Cat # 139303
PE anti-mouse CD 64 (FCγRI)	Biolegend	Clone X54-5/7.1Cat # 139303
PE-Cy5 anti-mouse/human CD 11b	Biolegend	Clone M1/70Cat # 101210
Brilliant Violet 650 rat anti-mouse I-A/I-E (MHC II)	Biolegend	Clone M5/114.15.2Cat # 107641
APC-Cy7 rat anti-mouse F4/80	Biolegend	Clone BM8Cat # 123117
BV785 hamster anti-mouse CD 11c	Biolegend	Clone N418Cat # 117336
PerCP-eFluor710 rat anti-mouse TIM-4	eBiosciences	Clone 54 (RMT4-54)Cat # 46-5866-28
Alexa Fluor 488 COX 2	Cell Signaling Technologies	Clone (D5H5) XP ®Cat # 13596S
PE-Dazzle 594 rat anti-mouse IL-10	Biolegend	Clone JES5-16E3Cat # 505034
Brilliant Violet mouse anti-mouse 421 TGF-β1	Biolegend	Clone TW7-16B4Cat # 141407
PE sheep anti-mouse Arginase 1	R&D	Cat # IC5868P
Alexa Fluor 647 rabbit- anti-human iNOS	Novus	Clone 4E5Cat # NBP2-22119AF647
TruStain Fc-blocking IgG (anti-mouse CD16/32)	Biolegend	Clone 93Cat # 101310
Bacterial and Virus Strains
Escherichia coli		Strain O6:K2:H1
Biological Samples
Leukocyte cones	GBS Re NHS Blood/Transplant	Cat # NC24
Chemicals, Peptides, and Recombinant Proteins
Ethanol, Absolute (200 proof), Mol Biology grade, Dnase, Rnase, Protease-free	Fisher Scientific Uk Ltd	Cat # 10644795
Methanol, Optima(TM) LC/MS grade	Fisher Scientific Uk Ltd	Cat # 10767665
Acetic acid	Fluka	Cat # 07692-1L-F
Methyl formate, 98% for spectroscopy	Fisher Scientific Uk Ltd	Cat # 10414315
n-Hexane; For HPLC; 97+%; Acros Organics	Fisher Scientific Uk Ltd	Cat # 11934421
Deuterium-labelled 5S-HETE	Cayman Chemicals	Cat # 10007276
Deuterium-labelled Leukotriene (LT) B4	Cayman Chemicals	Cat #: 320110
Deuterium-labelled Lipoxin (LX) A4	Cayman Chemicals	Cat #: 10007737
Deuterium-labelled Resolvin (Rv) D2	Cayman Chemicals	Cat #: 11184
Deuterium-labelled prostaglandin (PG) E2	Cayman Chemicals	Cat #: 314010
PGD2	Cayman Chemicals	Cat #: 10007202
PGE2	Cayman Chemicals	Cat #: 10007211
PGF2a	Cayman Chemicals	Cat # 16010
Thromboxane B2	Cayman Chemicals	Cat #: 10007237
LTB4	Cayman Chemicals	Cat #: 10007240
20-OH-LTB4	Cayman Chemicals	Cat # 20190
LXA4	Cayman Chemicals	Cat #: 10007271
LXB4	Cayman Chemicals	Cat #: 90420
5S,12S-diHETE	In-house biogenic synthesis (J Dalli)	(Borgeat et al., 1982)
5S,15S-diHETE	Cayman Chemicals	Cat #: 35280
15-epi-LXA4	Cayman Chemicals	Cat #: 90415
15-epi-LXB4	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	(Claria et al., 1996)
RvE1	Cayman Chemicals	Cat #: 10007848
RvE2	Custom synthesis	(Serhan et al., 2000)
RvE3	Custom synthesis	(Isobe et al., 2012)
RvD1	Cayman Chemicals	Cat #: 10012554
RvD2	Cayman Chemicals	Cat #: 10007279
RvD3	Cayman Chemicals	Cat #: 13834
RvD4	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	(Winkler et al., 2016)
RvD5	Cayman Chemicals	Cat #: 10007280
RvD6	In-house biogenic synthesis (J Dalli)	N/A
17R-RvD1	Cayman Chemicals	Cat #: 13060
17R-RvD3	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	Dalli et al., 2013b
Maresin (MaR) 1	Cayman Chemicals	Cat #: 10878
MaR2	Cayman Chemicals	Cat #: 16369
4S,14S-diHDHA	In-house biogenic synthesis (J Dalli)	(Serhan et al., 2009)
7S,14S-diHDHA	In-house biogenic synthesis (J Dalli)	(Serhan et al., 2009)
22-OH-MaR1	In-house biogenic synthesis (J Dalli)	(Colas et al., 2016)
14-oxo-MaR1	In-house biogenic synthesis (J Dalli)	(Colas et al., 2016)
Protectin (PD)1	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	(Petasis et al., 2012)
10S,17S-diHDHA	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	(Petasis et al., 2012)
22-OH-PD1	Custom Synthesis (Dr Trond V. Hansen, University of Oslo)	(Tungen et al., 2014b)
n-3 DPA	Cayman Chemicals	Item № 21907
RvD1n-3 DPA	In-house biogenic synthesis (J Dalli)	(Dalli et al., 2013a)
RvD2n-3 DPA	In-house biogenic synthesis (J Dalli)	Dalli et al. (2013a)
RvD5n-3 DPA	In-house biogenic synthesis (J Dalli)	Dalli et al. (2013a)
MaR1n-3 DPA	Custom Synthesis (Dr Trond V. Hansen, University of Oslo)	(Tungen et al., 2014a)
7S, 14S-diHDPA	In-house biogenic synthesis (J Dalli)	Dalli et al. (2013a)
PD1n-3 DPA	Custom Synthesis (Dr Trond V. Hansen, University of Oslo)	Aursnes et al. (2014)
PD2n-3 DPA	In-house biogenic synthesis (J Dalli)	Dalli et al. (2013a)
16S, 17S-ePDn-3 DPA	Custom Synthesis (Dr Trond V. Hansen, University of Oslo)	This paper
10S,17S-diHDPA	In-house biogenic synthesis (J Dalli)	Dalli et al. (2013a)
Δ15trans-PD1n-3 DPA	In-house biogenic synthesis (J Dalli)	This paper
10epi-Δ15trans-PD1n-3 DPA	In-house biogenic synthesis (J Dalli)	This paper
17R-PD1	Custom Synthesis (Dr Charles Serhan, Harvard Medical School)	Petasis et al. (2012)
RvT1	In-house biogenic synthesis (J Dalli)	(Dalli et al., 2015)
RvT2	In-house biogenic synthesis (J Dalli)	Dalli et al. (2015)
RvT3	In-house biogenic synthesis (J Dalli)	Dalli et al. (2015)
RvT4	In-house biogenic synthesis (J Dalli)	Dalli et al. (2015)
Histopaque – 1077	Sigma	Cat # 10771-100ML
Dulbecco’s phosphate buffer saline with MgCl2 and CaCl2 (PBS+/+)	Sigma	Cat # D8662
Dulbecco’s phosphate buffer saline without MgCl2 and CaCl2 (PBS-/-)	Sigma	Cat # D8537
RPMI-1640	Sigma	Cat # R8758
RPMI 1640 Medium, no glutamine, no phenol red	Gibco/Life Technologies	Cat # 32404014
Recombinant Human M-CSF	R&D	Cat # 216-MC-025
PD146176	Cambridge Bioscience	Cat # 10010518
Human serum type AB (male)	Sigma	Cat # H4522-100ML
Penicillin-Streptomycin	Sigma	Cat # P4333
Fetal bovine serum (FBS)	Gibco/Life Technologies	Cat # 105000-64
DMSO, cell culture reagent	ChemCruz	Cat # sc-358801
Bovine serum albumin (BSA)	Sigma	Cat # A9418
EDTA	Invitrogen	Cat # 15575-038
PKH26 Red Fluorescent Cell Linker kit	Sigma	Cat # PKH26GL-1KT
PKH67 Green Fluorescent Cell Linker kit	Sigma	Cat # PKH67GL-1KT
Trypan Blue	Sigma	Cat # T8154
Polybrene Transfection Reagent	Millipore, UK Ltd	Cat # TR-1003-G
Recombinant Human GM-CSF	Biolegend	Cat # 572902
Human recombinant INF-γ	Biolegend	Cat # 570206
Human recombinant IL-4	Biolegend	Cat # 574002
Lipopolysaccharides	Sigma	Cat # L2630
ALOX15 Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector (Gene ID = 246). 5μg purified plasmid DNA per construct	OriGENE	TL314822
MISSION shRNA Bacterial Clone ALXO15B	Sigma	Cat #s SHCLNG - TRCN0000432221, TRCN0000056583, TRCN0000056584, TRCN0000056585, TRCN0000056586
MISSION shRNA Bacterial Glycerol Stock EPHX2	Sigma	Cat #s SHCLNG - TRCN0000050553, TRCN0000050554, TRCN0000050555, TRCN0000050556, TRCN0000050557
MISSION® pLKO.1-puro Empty Vector Control Plasmid DNA	Sigma	Cat # SHC001
Trizma hydrochloride	Sigma	Cat # T3253
hr-ALOX15	Novus Biologicals	Cat # H00000246-P01
hr-ALOX15B	Cayman Chemicals	Cat # 10011263-100ug-CAY
hr-EPHX2	Cayman Chemicals	Cat # 10011669
AUDA	Sigma	Cat # SML0177
4% PFA solution	Affymetrix	Cat # 19943
Permeabilization buffer (10X)	eBiosciences	Cat # 00-8333-56
Fixation/Permeabilization Concentrate	eBiosciences	Cat # 00-5123-43
Fixation/Permeabilization Diluent	eBiosciences	Cat # 00-5223-56
Hanks Balanced Salt solution	Sigma	Cat # H6648
γ-Globulins from human blood (FC block)	Sigma	Cat # G4386-5G
LIVE/DEAD BacLight Bacterial Viability dye	Molecular Probes, Life Technologies	Cat # B35000
Critical Commercial Assays
APC Annexin V Apoptosis Detection Kit with PI	Biolegend	Cat # 640932
EasySep™ Human Monocyte Isolation Kit	StemCell Technologies	Cat # 19319
Experimental Models: Organisms/Strains
Mus musculus, NCBI Taxonomy ID:10090,C57BL/6/FVB	Charles River	JAX™ C57BL/6J
Mus musculus, NCBI Taxonomy ID:10090,C57BL/6/FVB 12/15-LOX KO	The Jackson Laboratory	B6.129S2-Alox15tm1Fun/JStock # 002778
Experimental Models: Cell lines
HL-60	ATCC	Cat # CCL-240
Software and Algorithms
FlowJo software	Tree Star, Ashland, OR	https://www.flowjo.com/solutions/flowjo/downloads
GraphPad Prism 6.0f	GraphPad Software, CA	https://www.graphpad.com/support/prism-6-updates/
SIMCA 14.1 software	Umetrics, Umea, Sweden	https://umetrics.com/kb/simca-141
IDEAS® (Image Data Exploration and Analysis Software, Version 6.0)	Amnis®, EMD Millipore	http://www.merckmillipore.com/GB/en/life-science-research/cell-analysis-flow-cytometry/amnis-imaging-flow-cytometers/analysis-acquisition-software/ideas-software/qe2b.qB.Oq8AAAFLQM8Jx34R,nav
Other
Isolute 500 mg / 3ml C18 SPE column	Biotage, Sweden	Cat # 220-0050-B
Poroshell 120 EC-18 4.6 mm ×100 mm × 2.7 μm reversed phase column	Agilent, USA	N/A
LSR Fortessa cell analyser	BD Biosciences, UK	N/A
Extra-Hera	Biotage, Sweden	N/A
TurboVap LV	Biotage, Sweden	N/A
Qtrap 5500/6500	AB Sciex	N/A
Shimadzu SIL-20AC auto-injector	Shimadzu Corp.	N/A
LC-20AD Binary pump	Shimadzu Corp.	N/A
FLUOstar Omega microplate reader	BMG Labtech	N/A
ImageStream X MK2 Imaging Flow Cytometer	Amnis®, EMD Millipore	N/A